Therefore, new drug modalities targeting ezrin may be effective for reducing the PD-L1 expression on the cell surface of human endometrial adenocarcinoma and providing a novel therapeutic option to enhance the response rate of ICB therapies. Here, EZR is linked to endometrium adenocarcinoma.